Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Biomedical Advanced Research and Development AuthorityBiomedical Advanced Research and Development Authority (BARDA) (HHSO100201400003I, HHSO10033002T)
This publication has 16 references indexed in Scilit:
- Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialOpen Forum Infectious Diseases, 2014
- Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 AdjuvantJAMA, 2014
- Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 AdjuvantOpen Forum Infectious Diseases, 2014
- Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade NeutralizationPLOS ONE, 2014
- Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older PersonsThe Journal of Infectious Diseases, 2012
- MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety databaseVaccine, 2009
- Correction: MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly AdultsPLOS ONE, 2009
- Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1New England Journal of Medicine, 2008
- Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in AdultsThe Journal of Infectious Diseases, 2008
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006